Spironolactone 5% | Dapsone 5.5% | Tea Tree Oil 5%

Route: Topical application to affected facial or body skin.

• Cleanse the skin with a gentle cleanser and pat dry before application.
• Apply a thin layer to the affected area(s) once or twice daily as directed by the prescriber.
• Avoid eyes, mucous membranes, and broken or inflamed skin not related to acne.
• Wash hands thoroughly after application.
• Allow to dry completely before applying makeup or sunscreen.
• Use consistently for at least 8–12 weeks for full effect assessment.

Prescriber-directed topical application. Generally applied once or twice daily to acne-affected areas. Consistency of use over 8–12 weeks is required before full therapeutic response can be assessed. Dose (application amount and frequency) is determined by the prescribing clinician based on severity and skin tolerance.

• Spironolactone (topical): Competes with testosterone and dihydrotestosterone (DHT) for androgen receptor binding in sebaceous gland cells; also inhibits 5α-reductase, reducing local DHT production; and may increase sex hormone-binding globulin (SHBG), reducing free androgen bioavailability. Net effect: reduced sebum production, decreased follicular plugging, and lower comedone formation—without the systemic antiandrogenic effects of oral spironolactone.
• Dapsone: Inhibits neutrophil myeloperoxidase and eosinophil peroxidase, suppressing hypochlorous acid production; scavenges reactive oxygen species; inhibits leukotriene B4-mediated neutrophil chemotaxis; has some in vitro activity against Cutibacterium acnes via dihydropterase synthase inhibition (analogous to sulfonamide mechanism). Anti-inflammatory properties are primary for topical acne application.
• Tea Tree Oil (terpinen-4-ol): Disrupts the structural and functional integrity of microbial cell membranes through partitioning into the lipid bilayer; causes leakage of cellular contents and inhibits microbial respiration; also attenuates histamine-mediated vasodilation and plasma extravasation (anti-inflammatory). Effective against C. acnes at concentrations ≥0.25%.

Indication context: This combination is prescribed for acne vulgaris with an androgenic component (hormonal acne), mixed inflammatory and comedonal presentations, particularly in patients who have not responded adequately to topical retinoids or antibiotics alone, or in whom oral antibiotics are not preferred. The combination addresses sebum overproduction (spironolactone), inflammation (dapsone), and bacterial load (tea tree oil and dapsone) simultaneously.

Monitoring:

• Assess lesion counts (inflammatory papules/pustules, comedones) at 8–12 weeks.
• Monitor for local skin irritation, contact dermatitis, or excessive dryness.
• No routine laboratory monitoring required for topical spironolactone at 5% (systemic absorption is minimal); however, in patients with renal impairment or on potassium-sparing medications, discuss systemic absorption potential with prescriber.
• G6PD deficiency: topical dapsone at ≤5% does not significantly increase hemolytic risk even in G6PD-deficient patients per clinical studies, but the prescriber should be aware of G6PD status.

Contraindications:

• Known hypersensitivity to spironolactone, dapsone (or sulfonamides), tea tree oil, or any excipient.
• Avoid on open wounds, infected skin lesions, or mucous membranes.

Warnings & Precautions:

• G6PD deficiency: topical dapsone at standard concentrations has not demonstrated clinically significant hemolysis, but use with caution and inform prescriber of G6PD status.
• Dapsone interaction with benzoyl peroxide: concurrent use of topical dapsone and benzoyl peroxide on the same area can cause temporary orange-yellow skin discoloration; use at different times of day or on separate areas.
• Tea tree oil: rare contact sensitization or allergic contact dermatitis; discontinue if hypersensitivity reaction occurs.
• Pregnancy: systemic antiandrogenic effects of spironolactone are relevant if absorbed; use with caution and only under prescriber direction during pregnancy.

Drug Interactions:

• Topical benzoyl peroxide: causes orange-yellow discoloration with dapsone; apply at different times of day.
• Systemic interactions of topical spironolactone and dapsone at therapeutic concentrations are not well characterized; minimal risk at 5% topical doses.

Common Side Effects: Application site dryness, scaling, erythema, or oiliness; mild skin irritation; rarely, contact dermatitis from tea tree oil sensitization.

Store at room temperature (15–25°C). Protect from direct light and heat. Keep tightly capped. Do not freeze. Tea tree oil is volatile at elevated temperatures—store in a cool, dry location. Use within the beyond-use date assigned by Genesis Compounding per USP <795> guidelines. Keep out of reach of children.

Why are three ingredients combined in one topical preparation?

Each ingredient addresses a different aspect of acne pathogenesis: spironolactone reduces androgen-driven sebum overproduction at the skin level; dapsone targets the inflammatory response and bacterial load; tea tree oil provides additional antimicrobial and anti-inflammatory activity. Combining them allows multi-mechanism treatment in a single application.

Can men use this preparation?

Topical spironolactone at 5% concentration acts locally on sebaceous gland androgen receptors with minimal systemic absorption. Men can use it without the systemic hormonal effects associated with oral spironolactone. However, prescribers should consider this on a patient-specific basis.

Why is my skin turning orange where I apply this?

If you use benzoyl peroxide concurrently in the same area, a chemical reaction between dapsone and benzoyl peroxide can cause a temporary orange-yellow discoloration. This is harmless and resolves on washing. Avoid applying both products to the same area simultaneously—apply them at different times of day.

How long before I see improvement?

Topical acne therapies typically require 8–12 weeks of consistent use before meaningful reduction in lesion counts is achieved. Do not discontinue early; continue use as directed by your prescriber and report your response at follow-up visits.

Is this FDA-approved?

Topical dapsone 5% gel (Aczone) and topical tea tree oil preparations are available commercially. There is no FDA-approved topical spironolactone product. This three-ingredient combination is a patient-specific 503A compounded preparation from Genesis Compounding.